The global Acute Myeloid Leukemia (AML) therapeutics market is set to expand significantly, with projections indicating growth from USD 3.8 billion in 2025 to USD 10.1 billion by 2036, according to a new report from Fact.MR. This represents a compound annual growth rate (CAGR) of 9.2% between 2026 and 2036, creating an absolute dollar opportunity of approximately USD 5.9 billion as the market nearly triples in value.
The growth is fueled by a paradigm shift from traditional chemotherapy toward genomics-driven treatment strategies and targeted therapies. As healthcare providers increasingly adopt molecular diagnostics and mutation-based treatment selection, AML management is becoming more personalized, aiming to improve patient outcomes and reduce disease recurrence.
Targeted therapies are expected to account for 36% of market share in 2026, making them the leading drug class. These mutation-specific drugs, targeting abnormalities like FLT3 and NPM1, offer enhanced efficacy and tolerability compared to conventional approaches. The newly diagnosed AML segment will hold 48% market share, as initial treatment regimens generate the highest therapy volumes.
Hospitals remain the primary treatment setting, capturing 55% of market demand due to the need for intensive inpatient management. Hospital pharmacies also dominate sales channels with a 49% share, reflecting the complexity of AML therapies requiring specialized handling.
One of the strongest growth drivers is the increasing availability of therapies for relapsed and refractory AML, including oral targeted therapies, menin inhibitors, and mutation-specific treatments. Recent regulatory approvals are expanding options for patients with limited alternatives.
Geographically, South Asia and East Asia are emerging as high-growth regions due to expanding cancer care infrastructure and access to molecular diagnostics. India is projected to grow at an 11.8% CAGR, China at 10.9%, while North America remains a revenue leader with an 8.7% CAGR.
Key players in the competitive landscape include AbbVie Inc., Genentech (Roche), Astellas Pharma Inc., Syndax Pharmaceuticals, and Kura Oncology, all investing heavily in precision medicine and clinical trials.
According to Shambhu Nath Jha, Principal Consultant at Fact.MR, "Acute myeloid leukemia therapeutics are becoming more mutation-specific and patient-risk driven. The future of AML treatment will increasingly depend on molecular testing, precision treatment selection, and therapies that balance efficacy with improved tolerability."
The full report is available at Fact.MR's AML Therapeutics Market Report.
